62
Participants
Start Date
October 5, 2017
Primary Completion Date
September 9, 2020
Study Completion Date
September 10, 2020
VX15/2503 + avelumab
Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
Northwell Health Cancer Institute, Lake Success
University of Rochester, Rochester
Virginia Cancer Specialists, PC, Fairfax
Mayo Clinic, Jacksonville
Moffitt Cancer Center, Tampa
Gabrail Cancer Center, Canton
Mayo Clinic, Rochester
Washington University School of Medicine, St Louis
Highlands Oncology Group, PA, Fayetteville
University of California Los Angeles (UCLA), Los Angeles
Providence Portland Medical Center, Portland
Merck KGaA, Darmstadt, Germany
INDUSTRY
Vaccinex Inc.
INDUSTRY